Glaxo Smith Kline’s decision to discontinue a popular children’s asthma inhaler, Flovent, more than two years ago has caused ...

Dupilumab yields larger improvements in lung function than several other biologics in patients with severe asthma.

A string of FDA approvals and late-stage clinical trials has expanded the toolkit for treating seasonal and environmental allergies, giving patients new ways to manage symptoms and, in some cases, ...

A major pharmaceutical company ended price hikes and monopoly protection over a life-saving asthma inhaler following two ...